On­col­o­gy pipeline chief Alessan­dro Ri­va joins the ex­o­dus at Gilead, head­ing to helm a biotech spin­off 4 days af­ter O'­Day's ar­rival as CEO

Daniel O’Day’s third work day as the new CEO of Gilead was marked by the de­par­ture of one of the com­pa­ny’s top re­search sci­en­tists.

Alessan­dro Ri­va, who joined Gilead just a lit­tle more than 2 years ago, is leav­ing his post as ex­ec­u­tive vice pres­i­dent of on­col­o­gy “to pur­sue an­oth­er op­por­tu­ni­ty.”

Min­utes lat­er, we learned that Ri­va is shift­ing over to lead the new biotech spin­off from In­dia’s Glen­mark, which will be based in the US. Ri­va will be CEO of the sub­sidiary com­pa­ny, which will have its own board. Glen­mark’s new biotech spin­off is heav­i­ly fo­cused on on­col­o­gy and T cells, with “five clin­i­cal and three pre­clin­i­cal as­sets in de­vel­op­ment, three clin­i­cal as­sets are cur­rent­ly in Phase 2b, and one as­set is like­ly to en­ter Phase 2b in FY20.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER